Aneesh Karkhanis

Dr. Aneesh Karkhanis

Simcyp (United Kingdom), Sheffield, UK
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
AKAneesh Karkhanis
Aneesh Karkhanis
HLHui Yuan Lam
Hui Yuan Lam
GVGopalakrishnan Venkatesan
Gopalakrishnan Venkatesan
SKSiew Kwan Koh
Siew Kwan Koh
CCChristina Li Lin Chai
Christina Li Lin Chai
ECEric Chun Yong Chan
Eric Chun Yong Chan

28 February 2024 in The EMBO Journal
Verified
Journal Article
Open access
UAUttkarsh Ayyangar
Uttkarsh Ayyangar
AKAneesh Karkhanis
Aneesh Karkhanis
HTHeather Tay
Heather Tay
AAAliya Farissa Binte Afandi
Aliya Farissa Binte Afandi
OBOindrila Bhattacharjee
Oindrila Bhattacharjee
SRSrikala Raghavan
Srikala Raghavan
Dysregulated macrophage responses and changes in tissue metabolism are hallmarks of chronic inflammation in the skin. However, the metabolic cues that direct and support macrophage functions in the skin are poorly understood. Here, we show that during sterile skin inflammation, the epidermis and macrophages uniquely depend on glycolysis and the TCA cycle, respectively. This compartmentalisation is initiated by ROS-induced HIF-1α stabilization leading to enhanced glycolysis in the epidermis. The end-product of glycolysis, lactate, is then exported by epithelial cells and utilized by the dermal macrophages to induce their M2-like fates through NF-κB pathway activation. In addition, we show that psoriatic skin disorder is also driven by such lactate metabolite-mediated crosstalk between the epidermis and macrophages. Notably, small-molecule inhibitors of lactate transport in this setting attenuate sterile inflammation and psoriasis disease burden, and suppress M2-like fate acquisition in dermal macrophages. Our study identifies an essential role for the metabolite lactate in regulating macrophage responses to inflammation, which may be effectively targeted to treat inflammatory skin disorders such as psoriasis.

16 March 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
AKAneesh Karkhanis
Aneesh Karkhanis
GVGopalakrishnan Venkatesan
Gopalakrishnan Venkatesan
RKRyuichi Kambayashi
Ryuichi Kambayashi
JLJacqueline Wen Hui Leow
Jacqueline Wen Hui Leow
MHMarcus Qingrui Han
Marcus Qingrui Han
ECEric Chun Yong Chan
Eric Chun Yong Chan
Cytochrome P4502J2 (CYP2J2) metabolizes arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs). Dronedarone, an antiarrhythmic drug prescribed for treatment of atrial fibrillation (AF) induces cardiac adverse effects (AEs) with poorly understood mechanisms. We previously demonstrated that dronedarone inactivates CYP2J2 potently and irreversibly, disrupts AA-EET pathway leading to cardiac mitochondrial toxicity rescuable via EET enrichment. In this study, we investigated if mitigation of CYP2J2 inhibition prevents dronedarone-induced cardiac AEs. We first synthesized a deuterated analogue of dronedarone (termed poyendarone) and demonstrated that it neither inactivates CYP2J2, disrupts AA-EETs metabolism nor causes cardiac mitochondrial toxicity in vitro. Our patch-clamp experiments demonstrated that pharmacoelectrophysiology of dronedarone is unaffected by deuteration. Next, we show that dronedarone treatment or CYP2J2 knockdown in spontaneously beating cardiomyocytes indicative of depleted CYP2J2 activity exacerbates beat-to-beat (BTB) variability reflective of proarrhythmic phenotype. In contrast, poyendarone treatment yields significantly lower BTB variability compared to dronedarone in cardiomyocytes indicative of preserved CYP2J2 activity. Importantly, poyendarone and dronedarone display similar antiarrhythmic properties in the canine model of persistent AF, while poyendarone substantially reduces beat-to-beat variability of repolarization duration suggestive of diminished proarrhythmic risk. Our findings prove that deuteration of dronedarone prevents CYP2J2 inactivation and mitigates dronedarone-induced cardiac AEs.

27 January 2018 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
AKAneesh Karkhanis
Aneesh Karkhanis
JLJacqueline Wen Hui Leow
Jacqueline Wen Hui Leow
THThilo Hagen
Thilo Hagen
ECEric Chun Yong Chan
Eric Chun Yong Chan
Dronedarone and amiodarone are structurally similar antiarrhythmic drugs. Dronedarone worsens cardiac adverse effects with unknown causes while amiodarone has no cardiac adversity. Dronedarone induces preclinical mitochondrial toxicity in rat liver and exhibits clinical hepatotoxicity. Here, we further investigated the relative potential of the antiarrhythmic drugs in causing mitochondrial injury in cardiomyocytes. Differentiated rat H9c2 cardiomyocytes were treated with dronedarone, amiodarone and their respective metabolites namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA). Intracellular ATP content, mitochondrial membrane potential (Δψm), and inhibition of carnitine palmitoyltransferase I (CPT1) activity and arachidonic acid (AA) metabolism were measured in H9c2 cells. Inhibition of electron transport chain (ETC) activities and uncoupling of ETC were further studied in isolated rat heart mitochondria. Dronedarone, amiodarone, NDBD and NDEA decreased intracellular ATP content significantly (IC50=0.49, 1.84, 1.07, 0.63 µM respectively) and dissipated Δψm potently (IC50=0.5, 2.94, 12.8, 7.38 µM respectively). Dronedarone, NDBD and NDEA weakly inhibited CPT1 activity while amiodarone (IC50>100 µM) yielded negligible inhibition. Only dronedarone inhibited AA metabolism to its regioisomeric epoxyeicosatrienoic acids (EETs) consistently and potently. NADH-supplemented ETC activity was inhibited by dronedarone, amiodarone, NDBD and NDEA (IC50=3.07, 5.24, 11.94, 16.16 µM respectively). Cytotoxicity, ATP decrease and Δψm disruption were ameliorated via exogenous pre-treatment of H9c2 cells with 11,12-EET and 14,15-EET. Our study confirmed dronedarone causes mitochondrial injury in cardiomyocytes by perturbing Δψm, inhibiting mitochondrial complex I, uncoupling ETC and dysregulating AA-EET metabolism. We postulate cardiac mitochondrial injury is one potential contributing factor to dronedarone-induced cardiac failure exacerbation.

1 December 2017 in Biochemical Pharmacology
Verified
Journal Article
Closed access
AKAneesh Karkhanis
Aneesh Karkhanis
NTNhan Dai Thien Tram
Nhan Dai Thien Tram
ECEric Chun Yong Chan
Eric Chun Yong Chan